WSE:MAB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Mabion S.A., a biotechnology company, engages in the development and implementation of various biotech drugs based on monoclonal antibody technology in Poland.


Snowflake Analysis

Moderate growth potential with weak fundamentals.

Share Price & News

How has Mabion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MAB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.6%

MAB

-2.5%

PL Biotechs

3.7%

PL Market


1 Year Return

-65.4%

MAB

60.2%

PL Biotechs

-16.4%

PL Market

Return vs Industry: MAB underperformed the Polish Biotechs industry which returned 61.1% over the past year.

Return vs Market: MAB underperformed the Polish Market which returned -17.9% over the past year.


Shareholder returns

MABIndustryMarket
7 Day5.6%-2.5%3.7%
30 Day7.4%2.6%9.7%
90 Day-39.0%52.3%-2.9%
1 Year-65.4%-65.4%60.5%60.2%-14.4%-16.4%
3 Year-73.8%-73.8%22.6%22.4%-20.5%-26.0%
5 Year-52.1%-52.1%-9.8%-11.6%-16.3%-26.4%

Price Volatility Vs. Market

How volatile is Mabion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mabion undervalued compared to its fair value and its price relative to the market?


Share Price vs. Fair Value

Below Fair Value: MAB (PLN25.45) is trading above our estimate of fair value (PLN25.2)

Significantly Below Fair Value: MAB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MAB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MAB is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MAB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MAB has negative assets, so we can't compare its PB Ratio to the PL Biotechs industry average.


Next Steps

Future Growth

How is Mabion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

52.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: MAB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MAB's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if MAB's revenue is forecast to grow faster than the Polish market.

High Growth Revenue: Insufficient data to determine if MAB's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MAB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Mabion performed over the past 5 years?

-18.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MAB is currently unprofitable.

Growing Profit Margin: MAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MAB is unprofitable, and losses have increased over the past 5 years at a rate of -18.5% per year.

Accelerating Growth: Unable to compare MAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).


Return on Equity

High ROE: MAB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Mabion's financial position?


Financial Position Analysis

Short Term Liabilities: MAB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MAB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MAB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MAB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MAB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MAB has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.7% each year.


Next Steps

Dividend

What is Mabion's current dividend yield, its reliability and sustainability?

0.47%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MAB's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

zł53k

CEO Compensation


CEO

Dirk Kreder

0.25

Tenure

zł53,000

Compensation

Mr. Dirk Kreder, PhD serves as the President of the Management Board at Mabion S.A. since March 2020 and serves as its Chief Executive Officer. He also graduated from the International Executive MBA Progr ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Mabion S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mabion S.A.
  • Ticker: MAB
  • Exchange: WSE
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł350.122m
  • Shares outstanding: 13.73m
  • Website: https://www.mabion.eu

Location

  • Mabion S.A.
  • gen. Mariana Langiewicza 60 Street
  • Konstantynów Lódzki
  • 95-050
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MABWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNAug 2010
0QGWLSE (London Stock Exchange)YesCommon Bearer SharesGBPLNAug 2010

Biography

Mabion S.A., a biotechnology company, engages in the development and implementation of various biotech drugs based on monoclonal antibody technology in Poland. The company is developing various drugs that are used in the treatment of cancer, autoimmune, and metabolic diseases. Its products include MabionCD20, MabionHER2, MabionEGFR, and MabionVEGF that are oncology drugs; and MabionVEGF_Fab drug. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 11:26
End of Day Share Price2020/06/03 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.